Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
penta-1,2,3,4,6-O-galloyl-beta-D-glucose
- Development stage
- Unknown
- Lead developer
- Clemson University
- Modality
- Small Molecules
- Administration
- Intra-arterial
01
Overview
penta-1,2,3,4,6-O-galloyl-beta-D-glucose (also known as pentagalloylglucose or PGG) is a naturally occurring hydrolyzable gallotannin polyphenol compound with diverse biological activities, including anti-inflammatory, antioxidant, and anti-tumor properties. In clinical development, it is being investigated as a localized endovascular therapy (using the Nectero EAST System) to stabilize and slow the growth of small- to medium-sized abdominal aortic aneurysms (AAAs). PGG works by binding with high affinity to extracellular matrix proteins, specifically elastin and collagen, in the aortic wall. This binding reinforces the structural integrity of the vessel, sterically hinders enzymatic degradation by matrix metalloproteinases (MMPs), and reduces the risk of aneurysm expansion and rupture.
- Other names
- 1,2,3,4,6-O-pentagalloylglucose1,2,3,4,6-penta-O-galloyl-beta-D-glucopyranose1,2,3,4,6-pentagalloyl-beta-D-glucopyranosebeta-pentagalloylglucosebeta-PGGpenta-O-galloyl-beta-D-glucosepentagalloylglucosePGG
02
Targets
ANTXR2 (Anthrax toxin receptor 2)ELN (Elastin)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on penta-1,2,3,4,6-O-galloyl-beta-D-glucose.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on penta-1,2,3,4,6-O-galloyl-beta-D-glucose.